摘要
目的评析在三阴乳腺癌化学治疗中给予乌苯美司片对患者免疫功能与骨髓抑制程度的影响。方法现选取浙江省嘉兴市中医医院收治的三阴乳腺癌患者108例作为本研究的研究对象,依据随机对照研究的方式将其划分为对照组(54例)与试验组(54例),2组均行AC-T方案(吡柔比星+环磷酰胺+多西他赛)化疗,试验组在此基础上予以乌苯美司片口服。通过流式细胞法测定2组患者治疗前后与化疗结束6个月静脉血T淋巴细胞亚群、自然杀伤细胞(NK细胞)免疫功能以及外周全血细胞指标的变化差异。结果试验组化疗前后的T淋巴细胞亚群与NK细胞变化差相较于对照组显著更小(P〈0.05),化疗6个月后试验组的T淋巴细胞亚群与NK细胞提高更为确切(P〈0.05);试验组化疗前后的外周全血细胞下降程度相较于对照组显著更小(P〈0.05),而化疗后6个月外周全血细胞均有所升高,与对照组差异显著(P〈0.05)。结论三阴乳腺癌化学治疗中应用乌苯美司片有助于减轻化疗药物对患者免疫功能的影响与骨髓抑制程度,患者得以顺利完成整个化疗过程,且近、远期不良反应少,保障患者预后,临床推广价值尤为显著。
Objective To evaluate the immune function and the degree of bone marrow suppression of ubenimex tablets on the treatment of patients with triple-negative breast cancer underwent chemotherapy.Methods108 cases in Jiaxing hospital of traditional Chinese medicine were randomly divided into the control group and the experimental group, 54 cases in each group.The two group were all treated with AC-T chemotherapy (pirarubicin+ cyclophosphamide + docetaxel).At this basis, the experimental group were given ubenimex.Flow cytometry was used to detect the changes of T lymphocyte subsets, natural killer cell (NK cell) immune function and peripheral blood cell parameters in the two groups before and after the treatment and 6 months after the treatment.ResultsCompared to the control group, the T lymphocyte subsets and NK cell changes in the experimental group before and after chemotherapy were significantly smaller (P〈0.05).The T lymphocyte subsets and NK cells in the experimental group were more accurate than those in the control group (P〈0.05).The peripheral blood cells in the experimental group were significantly smaller than those in the control group (P〈0.05).Compared with the control group, the whole blood cells increased significantly in the experimental group 6 months after chemotherapy(P〈0.05).ConclusionIt can help to reduce the effect of chemotherapeutic drugs on the immune function and bone marrow suppression which ubenimex tablets was used on the treatment patients with triple-negative breast cancer c.Patients can be successfully complete the chemotherapy process, and the long-term and short-term adverse reactions were less, prognosis is good, clinical promotion value is significant.
出处
《中国生化药物杂志》
CAS
2017年第5期326-328,共3页
Chinese Journal of Biochemical Pharmaceutics
关键词
三阴乳腺癌
化学治疗
乌苯美司片
淋巴细胞
triple-negative breast cancer
chemotherapy
ubenimex tablets
lymphocyte